<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40698099</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2501-2533</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Romanian journal of ophthalmology</Title><ISOAbbreviation>Rom J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Assessing the Role of Statins as an Adjunctive Anti-VEGF Therapy for Clinically Significant Macular Edema (CSME) in Type 2 Diabetes Mellitus.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>227</EndPage><MedlinePgn>219-227</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.22336/rjo.2025.35</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="UNASSIGNED">This study aimed to evaluate the effectiveness of statin therapy as an adjunctive treatment to anti-VEGF therapy in type 2 diabetic patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant macular edema (CSME).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">In this prospective, randomized interventional study, patients were randomized into two groups: Group A received low-dose atorvastatin (10-20 mg), and Group B received high-dose atorvastatin (30-40 mg). All participants also received three loading doses of intravitreal ranibizumab (0.5 mg) at monthly intervals, followed by pro re nata treatment over a six-month period. Primary outcomes included the number of anti-VEGF injections required, best-corrected visual acuity (BCVA), and central macular thickness (CMT). Serum VEGF levels were measured at baseline and six months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The mean number of injections over six months was 3.4, with no significant difference between Group A (3.55) and Group B (3.33) (p = 0.24). Group A demonstrated substantial improvement in BCVA at both 3 and 6 months, accompanied by a notable reduction in CMT. In contrast, Group B's BCVA improvement was only significant at 3 months, with less consistent CMT reduction at 6 months. Serum VEGF levels decreased in Group A but increased in Group B, though these changes were not statistically significant.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">The findings suggest that low-dose atorvastatin, when used in conjunction with anti-VEGF therapy, may provide superior functional and anatomical outcomes in patients with CSME compared to high-dose statin therapy. The observed reduction in central macular thickness and improvement in visual acuity indicate a potential adjunctive benefit of statins, likely due to their pleiotropic effects, including anti-inflammatory and anti-angiogenic properties. Although the number of injections required was similar between the groups, the better response in the low-dose group highlights the need for further investigation into the dose-dependent effects of statins in managing diabetic macular edema.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Low-dose atorvastatin (10-20 mg) as an adjunct to anti-VEGF therapy resulted in better functional and anatomical outcomes in diabetic patients with CSME compared to high-dose atorvastatin. These findings suggest potential additional benefits of low-dose statins in managing patients with chronic subdural hematoma (CSME).</AbstractText><CopyrightInformation>&#xa9; 2025 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Markan</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eye7 Chaudhary Eye Centre, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Aniruddha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cleveland Clinic, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katoch</LastName><ForeName>Deeksha</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhadada</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Vishali</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Reema</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>Rom J Ophthalmol</MedlineTA><NlmUniqueID>101677459</NlmUniqueID><ISSNLinking>2457-4325</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>A0JWA85V8F</RegistryNumber><NameOfSubstance UI="D000069059">Atorvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZL1R02VT79</RegistryNumber><NameOfSubstance UI="D000069579">Ranibizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069059" MajorTopicYN="Y">Atorvastatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003930" MajorTopicYN="Y">Diabetic Retinopathy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008266" MajorTopicYN="N">Macula Lutea</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="Y">Macular Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069579" MajorTopicYN="Y">Ranibizumab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="Y">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BCVA = Best Corrected Visual Acuity</Keyword><Keyword MajorTopicYN="N">CAD = Coronary Artery Disease</Keyword><Keyword MajorTopicYN="N">CKD = Chronic Kidney Disease</Keyword><Keyword MajorTopicYN="N">CMT = Central Macular Thickness</Keyword><Keyword MajorTopicYN="N">COVID = Coronavirus Disease</Keyword><Keyword MajorTopicYN="N">CSME</Keyword><Keyword MajorTopicYN="N">CSME = Clinically Significant Macular Edema</Keyword><Keyword MajorTopicYN="N">DM = Diabetes Mellitus</Keyword><Keyword MajorTopicYN="N">DME = Diabetic Macular Edema</Keyword><Keyword MajorTopicYN="N">ETDRS = Early Treatment Diabetic Retinopathy Study</Keyword><Keyword MajorTopicYN="N">FBS = Fating Blood Sugar</Keyword><Keyword MajorTopicYN="N">FFA = Fundus Fluorescein Angiography</Keyword><Keyword MajorTopicYN="N">HDL = High Density Lipoprotein</Keyword><Keyword MajorTopicYN="N">HTN = Hypertension</Keyword><Keyword MajorTopicYN="N">IOP = Intraocular Pressure</Keyword><Keyword MajorTopicYN="N">KFT = Kidney Function Tests</Keyword><Keyword MajorTopicYN="N">LDL = Low Density Lipoprotein</Keyword><Keyword MajorTopicYN="N">LFT = Liver Function Tests</Keyword><Keyword MajorTopicYN="N">NPDR = Non-Proliferative Diabetic Retinopathy</Keyword><Keyword MajorTopicYN="N">OCT = Optical Coherence Tomography</Keyword><Keyword MajorTopicYN="N">PRN = Pro Re Nata</Keyword><Keyword MajorTopicYN="N">PTH = Para Thyroid Hormone</Keyword><Keyword MajorTopicYN="N">SGOT = Serum Glutamic Oxaloacetic Transaminase</Keyword><Keyword MajorTopicYN="N">SGPT = Serum Glutamic Pyruvic Transaminase</Keyword><Keyword MajorTopicYN="N">SPSS = Statistical Package for Social Sciences</Keyword><Keyword MajorTopicYN="N">TG = Triglycerides</Keyword><Keyword MajorTopicYN="N">VEGF - Vascular Endothelial Growth Factor</Keyword><Keyword MajorTopicYN="N">adjunct therapy</Keyword><Keyword MajorTopicYN="N">anti-VEGF</Keyword><Keyword MajorTopicYN="N">diabetic retinopathy</Keyword><Keyword MajorTopicYN="N">statin therapy</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList><CoiStatement>The authors state no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40698099</ArticleId><ArticleId IdType="pmc">PMC12277995</ArticleId><ArticleId IdType="doi">10.22336/rjo.2025.35</ArticleId><ArticleId IdType="pii">RomJOphthalmol-69-219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes. 2015;6(1):92&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317321</ArticleId><ArticleId IdType="pubmed">25685281</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV The long-term incidence of macular edema. Ophthalmology. 1995 Jan;102(1):7&#x2013;16. doi: 10.1016/s0161-6420(95)31052-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0161-6420(95)31052-4</ArticleId><ArticleId IdType="pubmed">7831044</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology. 1992;99(1):58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">1741141</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1519&#x2013;26. doi: 10.1007/s00417-008-0884-6. Epub 2008 Jul 5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-008-0884-6</ArticleId><ArticleId IdType="pubmed">18604548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TY, Klein R, Islam FMA, Cotch MF, Folsom AR, Klein BEK, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2246042</ArticleId><ArticleId IdType="pubmed">16490489</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma R, Torres M, Pe&#xf1;a F, Klein R, Azen SP, Los Angeles Latino Eye Study Group Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology. 2004;111(7):1298&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234129</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1) Am J Pathol. 2000;156(5):1733&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876909</ArticleId><ArticleId IdType="pubmed">10793084</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A, McGuire PG, Rangasamy S. Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology. 2015;122(7):1375&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25935789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">19171208</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R, Abhiramamurthy V, Gupta V, Gupta A, Bhansali A. Effect of Multifactorial Intervention on Diabetic Macular Edema. Diabetes Care. 2006;29(2):463&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443911</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129(9):999&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">24352521</ArticleId></ArticleIdList></Reference><Reference><Citation>Golubovic-Arsovska M. Association of dyslipidaemia with macular oedema and hard exudates in diabetic maculopathy. Prilozi. 2007;28(2):149&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18356786</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol. 2004;137(4):675&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059707</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech AC, Mitchell P, Summanen PA, O&#x2019;Day J, Davis TME, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet Lond Engl. 2007;370(9600):1687&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17988728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879715</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21(11):1712&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701455</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105(6):739&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">11839631</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-Edged Role of Statins in Angiogenesis Signaling. Circ Res. 2002;90(6):737&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11934843</ArticleId></ArticleIdList></Reference><Reference><Citation>Dworacka M, Krzy&#x17c;ag&#xf3;rska E, Weso&#x142;owska A, Borowska M, Iskakova S, Dworacki G. Statins in low doses reduce VEGF and bFGF serum levels in patients with type 2 diabetes mellitus. Pharmacology. 2014;93(1-2):32&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24434301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekerbicer N, Gurpinar T, Sisman AR, Guvendi G, Camsari UM, Uysal N. Statins reduce testicular and ocular VEGF: A potential compromise to microcirculation. Microvasc Res. 2018;119:60&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">29678729</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina RJ, O&#x2019;Neill CL, Devine AB, Gardiner TA, Stitt AW. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PloS One. 2008;3(7):e2584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2440506</ArticleId><ArticleId IdType="pubmed">18612412</ArticleId></ArticleIdList></Reference><Reference><Citation>Giurgea AG, Margeta C, Maca T, Rezaie-Majd A, Bucek RA, Manavi M, et al. Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. J Cardiovasc Pharmacol. 2006;47(1):30&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424782</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97(1):61&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16377285</ArticleId></ArticleIdList></Reference><Reference><Citation>SEARCH Study Collaborative Group. Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007 Nov;154(5):815&#x2013;23. doi: 10.1016/j.ahj.2007.06.034. 823.e1-6. Epub 2007 Sep 6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2007.06.034</ArticleId><ArticleId IdType="pubmed">17967584</ArticleId></ArticleIdList></Reference><Reference><Citation>Photocoagulation for diabetic macular edema Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">2866759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J. 2003;24(3):225&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12590901</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694580</ArticleId><ArticleId IdType="pubmed">15822172</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8801446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6(9):1004&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828689</ArticleId><ArticleId IdType="pubmed">10973320</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 2001;495(3):159&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11334884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambarakji HJ, Nakazawa T, Connolly E, Lane AM, Mallemadugula S, Kaplan M, et al. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006;47(6):2623&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16723479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States. Ophthalmol Retina. 2018;2(12):1179&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">31047187</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Ju H, Sun M, Chen H. Serum Vascular Endothelial Growth Factor Levels Correlate with Severity of Retinopathy in Diabetic Patients: A Systematic Review and Meta-Analysis. Dis Markers. 2019;2019:9401628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6451802</ArticleId><ArticleId IdType="pubmed">31019585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaviarasan K, Jithu M, Arif Mulla M, Sharma T, Sivasankar S, Das UN, et al. Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance are potential risk factors for diabetic retinopathy. Metabolism. 2015;64(9):958&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">26004392</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalini M, Raghavulu BV, Annapurna A, Avinash P, Chandi V, Swathi N, et al. Correlation of various serum biomarkers with the severity of diabetic retinopathy. Diabetes Metab Syndr. 2017;11(Suppl 1):S451&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">28420575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis. 2009;15:1906&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751798</ArticleId><ArticleId IdType="pubmed">19784389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayerden Ebin&#xe7; F, Haksun E, Ulver DB, Ko&#xe7; E, Erten Y, Reis Altok K, et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern Med Tokyo Jpn. 2008;47(17):1511&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18758126</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlingemann RO, Van Noorden CJF, Diekman MJM, Tiller A, Meijers JCM, Koolwijk P, et al. VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes Care. 2013;36(6):1629&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661842</ArticleId><ArticleId IdType="pubmed">23321217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>